RxDoctor Payments Data

David Price

Optometrist · Valdosta, GANPI 1861591638

Payments from drug & device makers

$1,671in general payments, 2019–2025

Across 54 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$670
  • Coopervision Inc.$301
  • Johnson & Johnson Vision Care, Inc.$236
  • Rxsight Inc$121
  • Bausch & Lomb Americas Inc.$117
  • Novartis$103
  • plus $122 from 5 others

What the payments were for

  • Food & beverage$1,55093%
  • Gifts$1217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,671 in reported general payments places this provider in the 65th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$80,454
Medicare patients
434
Services billed
4,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost86$33,284
RestasisCyclosporine20$17,661
SimbrinzaBrinzolamide/Brimonidine Tart44$10,736
Travoprost63$9,646
RhopressaNetarsudil Mesylate25$8,296
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$3,333
Brimonidine Tartrate161$3,022
Loteprednol Etabonate18$2,755
Latanoprost279$2,408
Brinzolamide13$1,561
Timolol Maleate141$1,547
Dorzolamide Hcl44$845
Prednisolone Acetate21$582
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$307
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$23$50,945106 claims
AlconSimbrinza$670$10,73644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →